Cargando…

Overexpression of the orphan nuclear receptor NR2F6 is associated with improved survival across molecular subgroups in endometrial cancer patients

INTRODUCTION: NR2F6 (nuclear receptor subfamily 2 group F member 6, also called Ear-2) is known to be an orphan nuclear receptor that has been characterized as an intracellular immune checkpoint in effector T cells and, therefore, may control tumor development and growth. The prognostic impact of NR...

Descripción completa

Detalles Bibliográficos
Autores principales: Proppe, L., Jagomast, T., Beume, S., Klapper, L., Gitas, G., Köster, F., Perner, S., Rody, A., Ribbat-Idel, J., Hanker, L. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374721/
https://www.ncbi.nlm.nih.gov/pubmed/36884115
http://dx.doi.org/10.1007/s00432-023-04632-2
_version_ 1785078837153890304
author Proppe, L.
Jagomast, T.
Beume, S.
Klapper, L.
Gitas, G.
Köster, F.
Perner, S.
Rody, A.
Ribbat-Idel, J.
Hanker, L. C.
author_facet Proppe, L.
Jagomast, T.
Beume, S.
Klapper, L.
Gitas, G.
Köster, F.
Perner, S.
Rody, A.
Ribbat-Idel, J.
Hanker, L. C.
author_sort Proppe, L.
collection PubMed
description INTRODUCTION: NR2F6 (nuclear receptor subfamily 2 group F member 6, also called Ear-2) is known to be an orphan nuclear receptor that has been characterized as an intracellular immune checkpoint in effector T cells and, therefore, may control tumor development and growth. The prognostic impact of NR2F6 in endometrial cancers is evaluated in this study. MATERIALS AND METHODS: Expression analysis of NR2F6 in 142 endometrial cancer patients was performed by immunohistochemistry of primary paraffin‑embedded tumor samples. Staining intensity of positive tumor cells was automatically assessed semi-quantitatively, and results were correlated with clinicopathological characteristics and survival. RESULTS: Forty five of 116 evaluable samples (38.8%) showed an overexpression of NR2F6. This leads to an improvement of the overall survival (OS) and progression-free survival (PFS). In NR2F6-positive patients, the estimated mean OS was 156.9 months (95% confidence interval (CI) 143.1–170.7) compared to 106.2 months in NR2F6-negative patients (95% CI 86.2–126.3; p = 0.022). The estimated PFS differed by 63 months (152 months (95% CI 135.7–168.4) vs. 88.3 months (95% CI 68.5–108.0), p = 0.002). Furthermore, we found significant associations between NR2F6 positivity, MMR status, and PD1 status. A multivariate analysis suggests NR2F6 to be an independent factor influencing the OS (p = 0.03). CONCLUSION: In this study, we could demonstrate that there is a longer progression-free and overall survival for NR2F6-positive patients with endometrial cancer. We conclude that NR2F6 might play an essential role in endometrial cancers. Further studies are required to validate its prognostic impact. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00432-023-04632-2.
format Online
Article
Text
id pubmed-10374721
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-103747212023-07-29 Overexpression of the orphan nuclear receptor NR2F6 is associated with improved survival across molecular subgroups in endometrial cancer patients Proppe, L. Jagomast, T. Beume, S. Klapper, L. Gitas, G. Köster, F. Perner, S. Rody, A. Ribbat-Idel, J. Hanker, L. C. J Cancer Res Clin Oncol Research INTRODUCTION: NR2F6 (nuclear receptor subfamily 2 group F member 6, also called Ear-2) is known to be an orphan nuclear receptor that has been characterized as an intracellular immune checkpoint in effector T cells and, therefore, may control tumor development and growth. The prognostic impact of NR2F6 in endometrial cancers is evaluated in this study. MATERIALS AND METHODS: Expression analysis of NR2F6 in 142 endometrial cancer patients was performed by immunohistochemistry of primary paraffin‑embedded tumor samples. Staining intensity of positive tumor cells was automatically assessed semi-quantitatively, and results were correlated with clinicopathological characteristics and survival. RESULTS: Forty five of 116 evaluable samples (38.8%) showed an overexpression of NR2F6. This leads to an improvement of the overall survival (OS) and progression-free survival (PFS). In NR2F6-positive patients, the estimated mean OS was 156.9 months (95% confidence interval (CI) 143.1–170.7) compared to 106.2 months in NR2F6-negative patients (95% CI 86.2–126.3; p = 0.022). The estimated PFS differed by 63 months (152 months (95% CI 135.7–168.4) vs. 88.3 months (95% CI 68.5–108.0), p = 0.002). Furthermore, we found significant associations between NR2F6 positivity, MMR status, and PD1 status. A multivariate analysis suggests NR2F6 to be an independent factor influencing the OS (p = 0.03). CONCLUSION: In this study, we could demonstrate that there is a longer progression-free and overall survival for NR2F6-positive patients with endometrial cancer. We conclude that NR2F6 might play an essential role in endometrial cancers. Further studies are required to validate its prognostic impact. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00432-023-04632-2. Springer Berlin Heidelberg 2023-03-08 2023 /pmc/articles/PMC10374721/ /pubmed/36884115 http://dx.doi.org/10.1007/s00432-023-04632-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Proppe, L.
Jagomast, T.
Beume, S.
Klapper, L.
Gitas, G.
Köster, F.
Perner, S.
Rody, A.
Ribbat-Idel, J.
Hanker, L. C.
Overexpression of the orphan nuclear receptor NR2F6 is associated with improved survival across molecular subgroups in endometrial cancer patients
title Overexpression of the orphan nuclear receptor NR2F6 is associated with improved survival across molecular subgroups in endometrial cancer patients
title_full Overexpression of the orphan nuclear receptor NR2F6 is associated with improved survival across molecular subgroups in endometrial cancer patients
title_fullStr Overexpression of the orphan nuclear receptor NR2F6 is associated with improved survival across molecular subgroups in endometrial cancer patients
title_full_unstemmed Overexpression of the orphan nuclear receptor NR2F6 is associated with improved survival across molecular subgroups in endometrial cancer patients
title_short Overexpression of the orphan nuclear receptor NR2F6 is associated with improved survival across molecular subgroups in endometrial cancer patients
title_sort overexpression of the orphan nuclear receptor nr2f6 is associated with improved survival across molecular subgroups in endometrial cancer patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374721/
https://www.ncbi.nlm.nih.gov/pubmed/36884115
http://dx.doi.org/10.1007/s00432-023-04632-2
work_keys_str_mv AT proppel overexpressionoftheorphannuclearreceptornr2f6isassociatedwithimprovedsurvivalacrossmolecularsubgroupsinendometrialcancerpatients
AT jagomastt overexpressionoftheorphannuclearreceptornr2f6isassociatedwithimprovedsurvivalacrossmolecularsubgroupsinendometrialcancerpatients
AT beumes overexpressionoftheorphannuclearreceptornr2f6isassociatedwithimprovedsurvivalacrossmolecularsubgroupsinendometrialcancerpatients
AT klapperl overexpressionoftheorphannuclearreceptornr2f6isassociatedwithimprovedsurvivalacrossmolecularsubgroupsinendometrialcancerpatients
AT gitasg overexpressionoftheorphannuclearreceptornr2f6isassociatedwithimprovedsurvivalacrossmolecularsubgroupsinendometrialcancerpatients
AT kosterf overexpressionoftheorphannuclearreceptornr2f6isassociatedwithimprovedsurvivalacrossmolecularsubgroupsinendometrialcancerpatients
AT perners overexpressionoftheorphannuclearreceptornr2f6isassociatedwithimprovedsurvivalacrossmolecularsubgroupsinendometrialcancerpatients
AT rodya overexpressionoftheorphannuclearreceptornr2f6isassociatedwithimprovedsurvivalacrossmolecularsubgroupsinendometrialcancerpatients
AT ribbatidelj overexpressionoftheorphannuclearreceptornr2f6isassociatedwithimprovedsurvivalacrossmolecularsubgroupsinendometrialcancerpatients
AT hankerlc overexpressionoftheorphannuclearreceptornr2f6isassociatedwithimprovedsurvivalacrossmolecularsubgroupsinendometrialcancerpatients